Preparation, Characterization and In vivo Evaluation of Rosuvastatin Calcium Loaded Solid Lipid Nanoparticles

DOI:

https://doi.org/10.37285/ijpsn.2015.8.1.11

Authors

  • Kishan V
  • Suvarna G
  • Narender D

Abstract



Rosuvastatin calcium (RC), is a hypolipidemic drug, and has poor oral bioavailability of about 20% due to first-pass effect. For improving the oral bioavailability of RC, solid lipid nanoparticles (SLNs) were developed using triglycerides (tristearin, tripalmitin, and trimyristin). Hot homogenization followed by ultrasonication method was used to prepare RC-SLNs. The prepared SLNs were characterized for particle size, PDI, zeta potential (ZP), entrapment efficiency (EE) and drug content. In vitro release studies were performed in 0.1N HCl and pH 6.8 phosphate buffer of by open tube method. Physical stability the SLNs was observed at refrigerated temperature and room temperature for 60 days. Pharmacokinetics of RC- SLNs after oral administration, in male Wistar rats was studied. SLNs prepared with tristearin (Dyanasan-118) having size of 207.3 ± 8.52 nm, PDI of 0.344 ± 0.084, ZP of – 20.9 ± 4.88 mV with 97.06 ± 0.210 % EE were optimized. Differential scanning calorimetric (DSC) study revealed that no interaction between drug and lipid. In vitro release studies showed that more cumulative release of RC in     pH 6.8 phosphate buffer than in 0.1NHCl during 24 hours. The lyophilized SLN formulation was used in knowing morphology of SLNs and was found to have spherical shape with increased polydispersity by Scanning electron microscopy. Pharmacokinetic studies showed the relative oral bioavailability of SLNs was 2.2 fold when compared to that of a suspension (p<0.001). Taken together, the results are indicative of SLNs as lipid based carriers for improving the oral bioavailability of this drug by minimizing first pass metabolism.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Keywords:

Rosuvastatin calcium, Solid lipid nanoparticles, Triglycerides, Oral bioavailability, Pharmacokinetics

Downloads

Published

2015-02-28

How to Cite

1.
V K, G S, D N. Preparation, Characterization and In vivo Evaluation of Rosuvastatin Calcium Loaded Solid Lipid Nanoparticles. Scopus Indexed [Internet]. 2015 Feb. 28 [cited 2024 Jul. 16];8(1):2779-85. Available from: https://www.ijpsnonline.com/index.php/ijpsn/article/view/767

Issue

Section

Research Articles

References

Arik Dahan and Amnon Hoffman (2008). Rationalizing the Selection of Oral Lipid based Drug Delivery Systems by an in vitro Dynamic Lipolysis Model for Improved Oral Bioavailability of Poorly Water Soluble Drugs. J Contr Rel 129: 1-10.

Driscoll MC (2002). Lipid-based Formulations for Intestinal Lymphatic Delivery. Eur J Pharm Sci 15: 405-415.

Hu L, Tang X and Cui F (2004). Solid Lipid Nanoparticles (SLNs) to Improve Oral Bioavailability of Poorly Soluble Drugs. J Pharm Pharmacol 56: 1527-1535.

Lian Dong Hu, Qianbin Xing, Jian Meng and Chuang Shang (2010). Preparation and Enhanced Oral Bioavailability of Cryptotan-Shinone Loaded Solid Lipid Nanoparticles. AAPS Pharm SciTech 11(2): 582-587.

Mäder K and Müller RH (2000). Influence of Different Parameters on Reconstitution of Lyophilized SLN. Int J Pharm 196: 211-213.

Manjunath K and Venkateswarlu V (2005). Pharmacokinetics, Tissue Distribution and Bioavailability of Clozapine Solid Lipid Nanoparticles after Intravenous and Intraduodenal Administration. J Contr Rel 107: 215-228.

Mehnert W and Mäder K (2001). Solid Lipid Nanoparticles Production, Characterization and Applications. Advanced Drug Delivery Reviews 47:165-196.

Mühlen AZ, Schwarz C and Mehnert W (1998). Solid Lipid Nanoparticles (SLN) for Controlled Release Drug Delivery – Drug Release and Release Mechanism. Eur J Pharm Biopharm 45: 149-155.

Müller RH, Mehnert W and Lucks JS (1995). Solid Lipid Nanoparticles (SLN)—An Alternative Colloidal Carrier System for Controlled Drug Delivery. Eur J Pharm Biopharm 41: 62-69.

Müller RH, Mehnert W and Sven G (2000). Solid Lipid Nanoparticles (SLN) for Controlled Drug Delivery - A Review of the State of the Art. Eur J Pharm Biopharm 50: 161-177.

Müller RH, Mehnert W and Souto EB (2005). Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for Dermal Delivery. In: Bronaugh RL, Maibach HI, (Eds). Percutaneous Absorption: Drugs, Cosmetics, Mechanisms, Methods (Drugs and the Pharmaceutical Sciences). Marcel Dekker: New York. 719-738.

Narendar D and Kishan V (2014). Candesartan Cilexetil Loaded Solid Lipid Nanoparticles for Oral Delivery: Characterization, Pharmacokinetic and Pharmacodynamic Evaluation. Drug Delivery Early Online: 1-10. DOI: 10.3109/10717544. 2014. 914986.

Schwarz C and Mehnert W (1997). Freeze-Drying of Drug-Free and Drug-Loaded Solid Lipid Nanoparticles (SLN). Int J Pharm 157: 171-179.

Sevda RR, Ravetkar AS and Shirote PJ (2011). UV Spectrophotometric Estimation of Rosuvastatin Calcium and Fenofibrate in Bulk Drug and Dosage form using Simultaneous Equation Method. Int J ChemTech Res 3(2): 629-635.

Souto EB and Müller RH (2007). Lipid Nanoparticles (Solid Lipid Nanoparticles and Nanostructured Lipid Carriers) for Cosmetic, Dermal and Transdermal Applications. In: Thassu D, Deleers M, Pathak Y (Eds) Nanoparticulate Drug Delivery Systems: Recent Trends and Emerging Technologies. CRC Press. 213-233.

Souto EB, Almeida AJ and Müller RH (2007). Lipid Nanoparticles (SLN, NLC) for Cutaneous Drug Delivery: Structure, Protection and Skin Effects. J Biomed Nanotech 3: 317-331.

Üner M and Yener G (2007). Importance of Solid Lipid Nanoparticles (SLN) in various Administration Routes and Future Perspectives. Int J Nano 2(3): 289-300.

Vijaykumar N, Raviraj P, Venkateshwarlu V and Harisudhan T (2009). Development and Characterization of Solid Oral Dosage form Incorporating Candesartan Nanoparticles. Pharm Dev Tech 14(3): 290-298.

Vinay Kumar V, Raghavendra C, Rojarani K, Laxminarayana A, Ramakrishna S and Prakash VD (2012). Design and Evaluation of Polymer Coated Carvedilol Loaded Solid Lipid Nanoparticles to Improve the Oral Bioavailability: A Novel Strategy to Avoid Intraduodenal Administration. Colloids Surf B 95: 1-9.

Most read articles by the same author(s)